tbuckley/cabot-search huggingface dataset:
Editorial: Doctors and population.
Journal: BMJ (1973)

predominantly monarticular, the joint initially affected, usually the knee, being subject to recurrence in all but two cases.Intervals between attacks varied from two to four weeks to a year.In no case did the condition progress or develop into rheumatoid polyarthritis, and no crippling re- sulted.Nevertheless it is of interest to note that this vaccineinduced arthritis does recur, and rubella vaccine virus has been recovered from the synovial fluid three months after vaccination.As well as adding rubella vaccines to the list of iatrogenic arthropathiest0 this study draws attention to the possible role of acute viral infection as a trigger for other forms of arth- ritis.Happily the condition, though relapsing, does not become chronic, and treatment need be only of short duration to control of symptoms.
Immediate medical consequences of nuclear accidents. Lessons from Chernobyl
Authors: R. P. Gale
Journal: JAMA (1987)

The immediate medical response to the nuclear accident at the Chernobyl nuclear power station involved containment of the radioactivity and evacuation of the nearby population. The next step consisted of assessment of the radiation dose received by individuals, based on biological dosimetry, and treatment of those exposed. Medical care involved treatment of skin burns; measures to support bone marrow failure, gastrointestinal tract injury, and other organ damage (ie, infection prophylaxis and transfusions) for those with lower radiation dose exposure; and bone marrow transplantation for those exposed to a high dose of radiation. At Chernobyl, two victims died immediately and 29 died of radiation or thermal injuries in the next three months. The remaining victims of the accident are currently well. A nuclear accident anywhere is a nuclear accident everywhere. Prevention and cooperation in response to these accidents are essential goals. (<i>JAMA</i>1987;258:625-628)
Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer
Authors: Richard L. Schilsky, Donna Bertucci, Nicholas J. Vogelzang, Hedy L. Kindler, Mark J. Ratain
Journal: Journal of Clinical Oncology (2002)

PURPOSE: The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination. PATIENTS AND METHODS: Eligible patients had advanced solid tumors that had failed to respond to standard therapy or for which no standard therapy was available, measurable or assessable disease, Karnofsky performance status ≥ 70%, and acceptable organ function. Capecitabine was administered twice daily by mouth each day for 21 consecutive days followed by a 1-week break. Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break. RESULTS: Forty patients were enrolled onto the study, and 33 are fully assessable for toxicity. The most common toxicities during the first cycle of chemotherapy were neutropenia and mucositis. Only one patient treated at gemcitabine and capecitabine doses of 800 and 2000 mg/m 2 , respectively, met protocol-specified DLT criteria; however, at these doses 65% of successive cycles required dose reduction or delay for toxicity. No episodes of DLT were observed at gemcitabine and capecitabine doses of 1,000 and 1,660 mg/m 2 , respectively, and 70% of cycles of therapy were delivered without dose reduction or delay. Therefore, these doses are recommended for further study. Tumor responses were observed in patients with metastatic colorectal and pancreatic cancer. CONCLUSION: Gemcitabine and capecitabine can be combined with acceptable toxicity at nearly full doses. Antitumor activity of the combination merits further investigation in phase II studies.
Ozone Exposure Assessment in a Southern California Community
Authors: Lee-Jane Sally Liu, Ralph Delfino, Petros Koutrakis
Journal: Environmental Health Perspectives (1997)

An ozone exposure assessment study was conducted in a Southern California community. The Harvard ozone passive sampler was used to monitor cohorts of 22 and 18 subjects for 8 weeks during the spring and fall of 1994, respectively. Ozone exposure variables included 12-hr personal O3 measurements, stationary outdoor O3 measurements from a continuous UV photometer and from 12-hr Harvard active monitors, and time-activity information. Results showed that personal O3 exposure levels averaged one-fourth of outdoor stationary O3 levels, attributable to high percentages of time spent indoors. Personal O3 levels were not predicted well by outdoor measurements. A random-effect general linear model analysis indicated that variance in personal exposure measurements was largely accounted for by random error (59-82%), followed by inter-subject (9-18%) and between-day (9-23%) random effects. The microenvironmental model performs differently by season, with the regression model for spring cohorts exhibiting two times the R2 of the fall cohorts (R2 = 0.21 vs. 0.09). When distance from the stationary monitoring site, elevation, and traffic are taken into account in the microenvironmental models, the adjusted R2 increased almost twofold for the fall personal exposure data. The low predictive power is due primarily to the apparent spatial variation of outdoor O3 and errors in O3 measurements and in time-activity records (particularly in recording the use of air conditioning). This study highlights the magnitude of O3 exposure misclassification in epidemiological settings and proposes an approach to reduce exposure uncertainties in assessing air pollution health effects.
NEW SECRET ORDER FOR PHYSICIANS.TREATMENT OF IMPETIGO WITH FRANKLINIZATION.IRREGULAR HOURS AND SMALL PAY.BOARD OF HEALTH CAN NOT RESTRICT MODE OF LAYING FLOOR.CONNECTION BETWEEN NASAL AFFECTIONS AND PSYCHIATRY.
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ANGI-18. PERIOSTIN IS EXPRESSED BY PERICYTES AND PROMOTES ANGIOGENESIS UNDER THE CONTROL OF GLIAL TUMOR CELLS
Authors: Karin Huizer, Changbin Zhu, Caroline Cheng, Johan Kros, Dana A M Mustafa
Journal: Neuro-Oncology (2017)

Recently periostin was associated with glioma angiogenesis and in a glioma mouse model it was shown that periostin is expressed by glioma stem cells, and its expression attracks tumor associated macrophages that promote malignant growth of glioma. In previous work on human gliomas we found periostin as specifically expressed in blood vessels of glioma as compared to other proliferating blood vessels. We now explored the cells that specifically express periostin at the protein and RNA level in human gliomas of various malignancy grades. I addition, in functional studies using gene silencing in cell cultures we studied the effects of periostin on angiogenesis and explored its regulators. We found that periostin is mainly expressed by (PDGFR-pos) pericytes and that these cells occasionally may display glioma stem cell characteristics. Co-culture experiments revealed that conditioned medium of the glioma cell line U87 increased the periostin expression by pericytes. Silencing of POSTN in pericytes in co-cultures with endothelial cells resulted in reduced formation, length and branching of vascular tubules. We conclude that periostin expression is crucial for glioma angiogenesis. In human glioma it is foremost expressed by pericytes and its expression is stimulated by glial tumor cells. The putative glioma stemness of pericytes needs further exploration. Clearly, the data open new avenues of anti-angiogenic strategies for glioma.
Clarithromycin Therapy for Mycobacterium avium Complex Bacteremia
Authors: Jan T.M. van der Meer
Journal: Annals of Internal Medicine (1995)

Letters15 July 1995Clarithromycin Therapy for Mycobacterium avium Complex BacteremiaJan T.M. van der Meer and Sven A. DannerJan T.M. van der MeerSearch for more papers by this author and Sven A. DannerSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-2-199507150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Chaisson and colleagues [1] found a good bacteremia-decreasing effect of all dosage schedules used. An early survival advantage was seen with the 500-mg twice-daily dose compared with higher doses. According to the authors, this difference was not a result of more severely ill patients being assigned to receive the higher doses. The authors also contend that the poor survival of patients receiving the 2000-mg twice-daily dose may have been related to the intolerance to clarithromycin of patients assigned to this dose. There was no difference in the number of dose-limiting reactions between patients assigned to the 500-mg ...REFERENCE1. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med. 1994; 121:905-11. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1995Volume 123, Issue 2Page: 154-155KeywordsBacteremiaFeversMycobacterium avium complexRelative riskSweat Issue Published: 15 July 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Cancer Recurrence and Survival Associated With Dietary Patterns in Stage III Colon Cancer—Reply
Authors: Jeffrey Meyerhardt, Charles Fuchs
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Very Easy Death
Authors: Simone de Beauvoir
Journal: Annals of Internal Medicine (1997)

Brief Communications15 November 1997A Very Easy DeathSimone de BeauvoirSimone de BeauvoirAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-10-199711150-00006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail "There is no such thing as a natural death: nothing that happens to a man is ever natural, since his presence calls the world into question. All men must die: but for every man his death is an accident and, even if he knows it and consents to it, an unjustifiable violation."Simone de BeauvoirA Very Easy DeathTranslated by Patrick O'Brian; New York: GP Putnam's Sons; 1966Submitted by:Mark R. Tonelli, MDUniversity of Washington School of Medicine; Seattle, WA 98195 Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 1997Volume 127, Issue 10Page: 891-894 ePublished: 15 August 2000 Issue Published: 15 November 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
ANOTHER FRAUD CHECKED.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE RÔLE OF LYMPHATICS IN PNEUMONIC INFECTION OF THE LUNGS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Environment for Learning
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats:</i> Percentage* of Adults Aged 20–64 Years Whose Blood Cholesterol Was Checked by a Health Professional in the Past 12 Months,† by Race/Ethnicity§ — National Health Interview Survey,¶ United States, 2011 and 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The percentage of adults aged 20-64 years who had a blood cholesterol check by a health professional in the past 12 months increased from 56.0% in 2011 to 61.7% in 2016. From 2011 to 2016, there was an increase in the percentage of adults with a blood cholesterol check among Hispanic (49.0% to 56.7%), non-Hispanic white (56.8% to 62.5%), non-Hispanic black (60.8% to 65.6%), and non-Hispanic Asian (55.8% to 63.0%) persons. In both years, non-Hispanic black adults were more likely than non-Hispanic white adults to have had a blood cholesterol check, and Hispanic adults were the least likely to have had a blood cholesterol check.
The Low Sodium Cook Book: How to Prepare Tasteful Meals for the Low Sodium or Low Salt Diet—including Suggestions for the Low Sodium, Low Fat, Low Cholesterol Diet
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Grudge
Authors: Jo Persoon-Gundy
Journal: Annals of Internal Medicine (2014)

Ad Libitum17 June 2014The GrudgeJo Persoon-Gundy, MDJo Persoon-Gundy, MDFrom Burbank, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-0113 Audio Reading - “The Grudge” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Grudge," by J. Persoon-Gundy. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Slick as a viper,Fanged thoughts sink under skin,Laying carnivorous eggs,Like a spider wasp.Leaving slimy slug trails,The wriggling larvae,Pupate into corrosive hateSo strong I can hear it.The shrill wailing teakettle shriekOf pressure-cooked shouts, packed in lies,Crammed full and slammed shutLike my suitcase when I left you.Blame bubbles up from oily depths,Collecting in corners,Like the shriveled charIn a deep fryer, spewing smokeThat coats everything in a sticky black rime.With burning eyes and stained lungs,I crunch that angry, potato chip pain,‘Til the venom runs in my veins, I am poisoned.Jo Persoon-Gundy, MDBurbank, California Author, Article, and Disclosure InformationAffiliations: From Burbank, California.Current Author Address: Jo Persoon-Gundy, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “The Grudge” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Grudge," by J. Persoon-Gundy. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 June 2014Volume 160, Issue 12Page: 846KeywordsLungsPainVeinsVenoms ePublished: 17 June 2014 Issue Published: 17 June 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Snuff-induced hypertension in pheochromocytoma
Authors: M. McPhaul
Journal: JAMA (1984)

The dipping of snuff provoked paroxysmal hypertension that induced myocardial ischemia in a 69-year-old woman with pheochromocytoma. The diagnosis of her tumor was delayed by a report of a falsely low urine metanephrine level, resulting from interference with the metanephrine assay by meglumine present in the urine because of contrast coronary angiography performed on the day of urine collection. (<i>JAMA</i>1984;252:2860-2862)
Myelodysplastic Syndromes
Authors: Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, Maoko Naganuma
Journal: Journal of the National Comprehensive Cancer Network (2013)

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world
Authors: Zobair Younossi, Yusuf Yilmaz, Ming-Lung Yu, Mohammed El Kassas, Marlen Castellanos-Fernandez, Vincent Wai-Sun Wong, Vasily Isakov, Ajay Kumar Duseja, Nahúm Méndez-Sanchez, George Papatheodoridis, Wah-Kheong Chan, Jacob George, Jian-Gao Fan, Elisabetta Bugianesi, Yuichiro Eguchi, Ziad H. Younes, Manuel Romero Gomez, Stuart Roberts, Stuart C. Gordon, Saeed Hamid, Aijaz Ahmed, Janus Ong, Saleh Alqahtani, Brian Lam, Mariam Ziayee, Issah Younossi, Fatema Nader, Andrei Racilla, Maria Stepanova
Journal: Journal of Hepatology (2020)